Table 1.
Studies’ Characteristics
| Article | Age group Study | Year | No | Age | Age group | Males % | HR | BSA/Weight | SBP | DBP | LV mass | EDV | ESV | EDD | ESD | Control studied | Disease studied |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| g/m2 | ml/m2 | ml/m2 | |||||||||||||||
| 1 | Bussadori [30] | 2009 | 15 | 8 ± 2 y | 5-9 y | 53 | Healthy Subjects | Healthy Pediatric Cohort | |||||||||
| 2 | Pettersen [21] | 2009 | 22 | 12.7 ± 2.3 y | 10-14 y | 63 | 1.44 ± 0.24 | 108 ± 12 | 63 ± 7 | 58 ± 8 | 26 ± 4 | Healthy Controls | Transposition of the Great Arteries | ||||
| 3 | Jin Yu [19] | 2010 | 35 | 2.6 ± 1.6 y | 1-4 y | 48 | 0.59 ± 0.15 | 59.5 ± 12.2 | 31.1 ± 5 | 19.7 ± 3.3 | Healthy Controls | Kawasaki Disease | |||||
| 4 | Van der Hulst [35] | 2010 | 19 | 14.1 ± 2.4 y | 10-14 y | 63 | 1.6 ± 0.3 | 95 ± 10 | 42 ± 7 | Healthy Controls | Tetralogy of Fallot | ||||||
| 5 | Koh [32] | 2010 | 9 | 5.5 ± 5.5 y | 5-9 y | 22 | 0.81 ± 0.44 | Healthy Controls | Left ventricular non-compaction | ||||||||
| 6 | Singh [41] | 2010 | 14 | 15 y | 15-19 y | 45 | 75 | 1.22 (1.1-1.6) | Healthy Controls | Single ventricle s/p Fontan procedure. | |||||||
| 7 | Cheung [44] | 2010 | 44 | 16.4 ± 6.9 y | 15-19 y | 48 | 54.1 ± 11.9 | 45 ± 5 | 28 ± 4 | Healthy Controls | Anthracycline Therapy | ||||||
| 8 | Takayasu [29] | 2011 | 12 | 7.4 ± 1.7 y | 5-9 y | 66 | 46.7 ± 4.8 | 13.5 ± 1.5 | Healthy Controls | Repaired Tetralogy of Fallot | |||||||
| 8 | Takayasu [29] | 2011 | 19 | 15.5 ± 4.1 y | 15-19 y | 70 | 54.9 ± 7.7 | 15 ± 2.6 | Healthy Controls | Repaired Tetralogy of Fallot | |||||||
| 9 | Marcus [11] | 2011 | 24 | 0.3 ± 0.3 y | 0-1 y | 54 | 118 | 0.32 ± 0.1 | 82.8 ± 8 | 56 ± 6 | 36.2 ± 12.1 | Healthy Subjects | Healthy Pediatric Cohort | ||||
| 9 | Marcus [11] | 2011 | 34 | 2.9 ± 1.0 y | 1-4 y | 56 | 101 | 0.62 ± 0.1 | 98 ± 10 | 62 ± 10 | 48.5 ± 11.6 | Healthy Subjects | Healthy Pediatric Cohort | ||||
| 9 | Marcus [11] | 2011 | 36 | 7.2 ± 1.2 y | 5-9 y | 69 | 84 | 0.93 ± 0.12 | 104 ± 8 | 70 ± 8 | 57.2 ± 12.3 | Healthy Subjects | Healthy Pediatric Cohort | ||||
| 9 | Marcus [11] | 2011 | 29 | 12.8 ± 1.6 y | 10-14 y | 55 | 77 | 1.43 ± 0.23 | 110 ± 10 | 72 ± 8 | 59.9 ± 14.2 | Healthy Subjects | Healthy Pediatric Cohort | ||||
| 9 | Marcus [11] | 2011 | 21 | 17 ± 1.3 y | 15-19 y | 43 | 65 | 1.81 ± 0.2 | 116 ± 10 | 75 ± 9 | 71.8 ± 16 | Healthy Subjects | Healthy Pediatric Cohort | ||||
| 10 | Di Salvo [34] | 2012 | 45 | 11 ± 3 y | 10-14 y | 65 | 78 | 1.32 ± 0.4 | 107 ± 14 | 61 ± 8 | 72 ± 15 | 38.9 ± 6.2 | Healthy Controls | Heterozygous Familial Hypercholesterolemia | |||
| 11 | Fernandes [45] | 2012 | 71 | 10 ± 5 y | 10-14 y | Healthy Controls | Tetralogy of Fallot | ||||||||||
| 12 | Poterucha [37] | 2012 | 19 | 15.3 ± 3 y | 15-19 y | 57 | 62 | 1.7 ± 0.3 | 119 ± 12 | 48 ± 5 | 30 ± 3.4 | Healthy Controls | Anthracycline Chemotherapy | ||||
| 13 | Hirth [43] | 2012 | 34 | 11.7 ± 3.8 y | 10-14 y | 62 | 70 | 1.41 ± 0.39 | 72.3 ± 16.9 | Healthy Controls | Renal Transplantation in Childhood | ||||||
| 14 | Schubert [27] | 2013 | 30 | 135-207 h | Neonates | 36 | Healthy Neonates | Fetuses | |||||||||
| 15 | Sehgal [17] | 2013 | 21 | 2-5 d | Neonates | 3912 g | Healthy Controls | Asphyxiated Infants | |||||||||
| 16 | Klitsie [28] | 2013 | 28 | 1-3 d | Neonates | 36 | 123 | 3500 g | Healthy Subjects | Healthy Newborns | |||||||
| 17 | Klitsie [12] | 2013 | 37 | 0.1-0.3 y | 0-1 y | 46 | 148 | 0.3 ± 0.1 | Healthy Subjects | Healthy Pediatric Cohort | |||||||
| 17 | Klitsie [12] | 2013 | 35 | 2.3-3.8 y | 1-4 y | 54 | 107 | 0.6 ± 0.1 | Healthy Subjects | Healthy Pediatric Cohort | |||||||
| 17 | Klitsie [12] | 2013 | 37 | 6.2-8.2 y | 5-9 y | 54 | 88 | 0.9 ± 0.2 | Healthy Subjects | Healthy Pediatric Cohort | |||||||
| 17 | Klitsie [12] | 2013 | 45 | 11.1-13.8 y | 10-14 y | 76 | 71 | 1.4 ± 02 | Healthy Subjects | Healthy Pediatric Cohort | |||||||
| 17 | Klitsie [12] | 2013 | 18 | 15.9-16.9 y | 15-19 y | 44 | 71 | 1.8 ± 0.2 | Healthy Subjects | Healthy Pediatric Cohort | |||||||
| 18 | Singh [42] | 2013 | 20 | 12.9 y | 10-14 y | 45 | 75 | 1.22 | 109 ± 11 | 68 ± 5 | Healthy Subjects | Tricuspid Atresia s/p Fontan procedure | |||||
| 19 | Van der Ende [5] | 2013 | 40 | 8.4 ± 4 y | 5-9 y | 53 | 1.07 ± 0.34 | Healthy Controls | Aortic Stenosis and Coarctation of Aorta | ||||||||
| 20 | Dogan [31] | 2013 | 52 | 6.4 ± 3.8 y | 5-9 y | 75 | 101 | 0.87 ± 0.32 | 56.1 ± 18.4 | 33.8 ± 7.4 | 17.8 ± 5.8 | Healthy Controls | Aortic Stenosis | ||||
| 21 | Barbosa [36] | 2013 | 46 | 11.5 ± 3.1 y | 10-14 y | 74 | 90.5 ± 10 | 58.1 ± 6.3 | 40.7 ± 5.6 | 25.9 ± 3.3 | Healthy Controls | Obese Patients | |||||
| 22 | McCandless [40] | 2013 | 22 | 12-29 m | 1-4 y | 55 | 0.48 | Healthy Controls | Kawasaki Disease | ||||||||
| 23 | Ryan [46] | 2013 | 61 | 5.2 ± 0.2 y | 5-9 y | 100 | 87 | 104 ± 1 | 60.9 ± 0.9 | Healthy Controls | Duchenne Muscular Dystrophy | ||||||
| 24 | Simsek [38] | 2013 | 20 | 16.4 ± 1.8 y | 15-19 y | 100 | 65 | 115 ± 10 | 70.5 ± 6 | 88 ± 14 | 46.7 ± 4.7 | 29.3 ± 4.3 | Healthy Controls | Young Elite Athletes | |||
| 25 | Vitarelli [20] | 2014 | 40 | 11.3 ± 2.8 y | 10-14 y | 55 | 76 | 103 ± 1.6 | 67.3 ± 1.4 | 54.1 ± 14.1 | 57.2 ± 9.5 | 41.2 ± 5.3 | Healthy Controls | Hypercholesterolemic and Obese Children | |||
| 26 | Forsey [33] | 2014 | 28 | 9.8 ± 4.4 y | 5-9 y | 82 | 1.16 ± 0.4 | 64.3 ± 11.5 | 41.8 ± 5.7 | Healthy Controls | Hypertrophic Cardiomyopathy Mutations | ||||||
| 27 | Labombarda [39] | 2014 | 79 | 11.8 ± 3.2 y | 10-14 y | 53 | 76 | 1.27 ± 0.29 | 109 ± 11 | 62.9 ± 8.1 | 42.5 ± 6.7 | Healthy Controls | Diabetic Children | ||||
| 28 | Binnetoglu [16] | 2015 | 31 | 15 (11-16) y | 15-19 y | 67 | 1.48 ± 0.24 | 110 (80-129) | 60 (48-80) | 67.7 ± 13 | 42.2 ± 2.48 | 26.1 ± 3.74 | Healthy Controls | Obese Children and Adolescents |
HR heart rate, BSA Body surface area, SBP systolic blood pressure, DBP diastolic blood pressure, EDV end diastolic volume, ESV end systolic volume, EDD end diastolic diameter, ESD end systolic diameter